Details of the Drug

General Information of Drug (ID: DMEN6X7)

Drug Name

Atropine

Synonyms

dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate

Indication

Disease Entry	ICD 11	Status	REF
Organophosphate poisoning	NE6Z	Approved	[1]
Poison intoxication	NE6Z	Phase 1	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

289.4

Logarithm of the Partition Coefficient (xlogp)

1.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 7.6 mL/min/kg [3]
Elimination: 57% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.0 +/-0.9 hours [3]
Metabolism: The drug is metabolized via the enzymatic hydrolysis in the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.61% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.3 L/kg [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.002 mg/mL [2]

Chemical Identifiers

Formula: C17H23NO3
IUPAC Name: [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
Canonical SMILES: CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
InChI: InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
InChIKey: RKUNBYITZUJHSG-PJPHBNEVSA-N

Cross-matching ID

PubChem CID: 174174
ChEBI ID: CHEBI:16684
CAS Number: 51-55-8
DrugBank ID: DB00572
TTD ID: D0RG3O
VARIDT ID: DR00665
ACDINA ID: D00851

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M5 (CHRM5)	TTH18TF	ACM5_HUMAN	Antagonist	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[7]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[8]
Cell division cycle protein 20 homolog (CDC20)	OTCOEZRV	CDC20_HUMAN	Gene/Protein Processing	[9]
Cyclin-A1 (CCNA1)	OTX4HD45	CCNA1_HUMAN	Gene/Protein Processing	[9]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Gene/Protein Processing	[9]
DNA replication licensing factor MCM4 (MCM4)	OT19PNNG	MCM4_HUMAN	Gene/Protein Processing	[9]
DNA replication licensing factor MCM6 (MCM6)	OTKLIAWT	MCM6_HUMAN	Gene/Protein Processing	[9]
G1/S-specific cyclin-E1 (CCNE1)	OTLD7UID	CCNE1_HUMAN	Gene/Protein Processing	[9]
G1/S-specific cyclin-E2 (CCNE2)	OTBBUKQQ	CCNE2_HUMAN	Gene/Protein Processing	[9]
Muscarinic acetylcholine receptor M1 (CHRM1)	OTKW3E6B	ACM1_HUMAN	Gene/Protein Processing	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Atropine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Atropine when combined with Bethanechol.	Abnormal micturition [MF50]	[11]
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Atropine due to adsorption of Sodium bicarbonate.	Acidosis [5C73]	[12]
Oliceridine	DM6MDCF	Moderate	Additive antimotility effects by the combination of Atropine and Oliceridine.	Acute pain [MG31]	[13]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Atropine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[14]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Atropine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Atropine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Atropine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Atropine and Memantine.	Alzheimer disease [8A20]	[14]
Galantamine	DMEO794	Moderate	Antagonize the effect of Atropine when combined with Galantamine.	Alzheimer disease [8A20]	[16]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Atropine when combined with Rivastigmine.	Alzheimer disease [8A20]	[16]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Atropine when combined with Donepezil.	Alzheimer disease [8A20]	[17]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Atropine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Atropine and Cariprazine.	Bipolar disorder [6A60]	[14]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Atropine and Loperamide.	Bowel habit change [ME05]	[18]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Atropine when combined with Acetylcholine.	Cataract [9B10]	[19]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Atropine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[20]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Atropine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[20]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Atropine and Dihydrocodeine.	Chronic pain [MG30]	[21]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Atropine and Olopatadine.	Conjunctiva disorder [9A60]	[22]
Alfentanil	DMVO0UB	Moderate	Additive antimotility effects by the combination of Atropine and Alfentanil.	Corneal disease [9A76-9A78]	[13]
Arbutamine	DMCY8AF	Moderate	Increased risk of rapid heart rate by the combination of Atropine and Arbutamine.	Coronary atherosclerosis [BA80]	[23]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Atropine and Ethanol.	Cystitis [GC00]	[24]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Atropine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[14]
Isocarboxazid	DMAF1NB	Minor	Additive anticholinergic effects by the combination of Atropine and Isocarboxazid.	Depression [6A70-6A7Z]	[14]
Tranylcypromine	DMGB5RE	Minor	Additive anticholinergic effects by the combination of Atropine and Tranylcypromine.	Depression [6A70-6A7Z]	[14]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Atropine and OPC-34712.	Depression [6A70-6A7Z]	[14]
Phenelzine	DMHIDUE	Minor	Additive anticholinergic effects by the combination of Atropine and Phenelzine.	Depression [6A70-6A7Z]	[14]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Atropine and Clomipramine.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Atropine and Doxepin.	Depression [6A70-6A7Z]	[15]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Atropine and Maprotiline.	Depression [6A70-6A7Z]	[14]
Nitroglycerin	DMQ2491	Minor	Decreased dissolution of Atropine taken sublingually caused by Nitroglycerin.	Diabetic foot ulcer [BD54]	[25]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Atropine and Mepenzolate.	Digestive system disease [DE2Z]	[14]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Atropine and Oxybutynine.	Discovery agent [N.A.]	[14]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Atropine and Meclizine.	Dizziness and giddiness [MB48]	[14]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Atropine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Atropine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[14]
Nadolol	DMW6GVL	Moderate	Antagonize the effect of Atropine when combined with Nadolol.	Essential hypertension [BA00]	[12]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Atropine and Solifenacin.	Functional bladder disorder [GC50]	[14]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Atropine and Tolterodine.	Functional bladder disorder [GC50]	[14]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Atropine due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[27]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Atropine and Propantheline.	Gastric ulcer [DA60]	[14]
Cisapride	DMY7PED	Moderate	Antagonize the effect of Atropine when combined with Cisapride.	Gastro-oesophageal reflux disease [DA22]	[28]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Atropine when combined with Isoflurophate.	Glaucoma [9C61]	[19]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Atropine when combined with Pilocarpine.	Glaucoma [9C61]	[11]
Carvedilol	DMHTEAO	Moderate	Antagonize the effect of Atropine when combined with Carvedilol.	Heart failure [BD10-BD1Z]	[12]
Chlorothiazide	DMLHESP	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Chlorothiazide.	Heart failure [BD10-BD1Z]	[29]
Hydroflumethiazide	DMVPUQI	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[29]
Acebutolol	DM0TI4U	Moderate	Antagonize the effect of Atropine when combined with Acebutolol.	Hypertension [BA00-BA04]	[12]
Bisoprolol	DM3UZ95	Moderate	Antagonize the effect of Atropine when combined with Bisoprolol.	Hypertension [BA00-BA04]	[12]
Penbutolol	DM4ES8F	Moderate	Antagonize the effect of Atropine when combined with Penbutolol.	Hypertension [BA00-BA04]	[12]
Nebivolol	DM7F1PA	Moderate	Antagonize the effect of Atropine when combined with Nebivolol.	Hypertension [BA00-BA04]	[12]
Pindolol	DMD2NV7	Moderate	Antagonize the effect of Atropine when combined with Pindolol.	Hypertension [BA00-BA04]	[12]
Indapamide	DMGN1PW	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Indapamide.	Hypertension [BA00-BA04]	[29]
Trichlormethiazide	DMHAQCO	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Trichlormethiazide.	Hypertension [BA00-BA04]	[29]
Labetalol	DMK8U72	Moderate	Antagonize the effect of Atropine when combined with Labetalol.	Hypertension [BA00-BA04]	[12]
Hydrochlorothiazide	DMUSZHD	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Hydrochlorothiazide.	Hypertension [BA00-BA04]	[29]
Potassium chloride	DMMTAJC	Major	Altered absorption of Atropine due to GI dynamics variation caused by Potassium chloride.	Hypo-kalaemia [5C77]	[30]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Atropine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[14]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Atropine and Amantadine.	Influenza [1E30-1E32]	[31]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Atropine and Propiomazine.	Insomnia [7A00-7A0Z]	[14]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Atropine and ITI-007.	Insomnia [7A00-7A0Z]	[14]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Atropine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[32]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Atropine and Clidinium.	Irritable bowel syndrome [DD91]	[14]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Atropine and Dicyclomine.	Irritable bowel syndrome [DD91]	[14]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Atropine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[16]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Atropine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[33]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Atropine and Lasmiditan.	Migraine [8A80]	[34]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Atropine and Flibanserin.	Mood disorder [6A60-6E23]	[35]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Atropine when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[36]
Edrophonium	DMCRQHB	Moderate	Antagonize the effect of Atropine when combined with Edrophonium.	Myasthenia gravis [8C6Y]	[36]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Atropine when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[36]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Atropine and Phenindamine.	Nasopharyngitis [CA00]	[14]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Atropine and Dimenhydrinate.	Nausea/vomiting [MD90]	[14]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Atropine and Promethazine.	Nausea/vomiting [MD90]	[14]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Atropine and Cyclizine.	Nausea/vomiting [MD90]	[14]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Atropine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[37]
Polythiazide	DMCH80F	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[29]
Pentazocine	DM1XBHS	Moderate	Additive antimotility effects by the combination of Atropine and Pentazocine.	Pain [MG30-MG3Z]	[13]
Dextropropoxyphene	DM23HCX	Moderate	Additive CNS depression effects by the combination of Atropine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[21]
Butorphanol	DM5KYPJ	Moderate	Additive antimotility effects by the combination of Atropine and Butorphanol.	Pain [MG30-MG3Z]	[13]
Oxymorphone	DM65AGJ	Moderate	Additive antimotility effects by the combination of Atropine and Oxymorphone.	Pain [MG30-MG3Z]	[13]
Levorphanol	DMGS80V	Moderate	Additive antimotility effects by the combination of Atropine and Levorphanol.	Pain [MG30-MG3Z]	[13]
Dezocine	DMJDB0Y	Moderate	Additive antimotility effects by the combination of Atropine and Dezocine.	Pain [MG30-MG3Z]	[13]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Atropine and Flavoxate.	Pain [MG30-MG3Z]	[14]
Nalbuphine	DMOSQGU	Moderate	Additive antimotility effects by the combination of Atropine and Nalbuphine.	Pain [MG30-MG3Z]	[13]
Buprenorphine	DMPRI8G	Moderate	Additive antimotility effects by the combination of Atropine and Buprenorphine.	Pain [MG30-MG3Z]	[13]
Hydrocodone	DMQ2JO5	Moderate	Additive antimotility effects by the combination of Atropine and Hydrocodone.	Pain [MG30-MG3Z]	[13]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Atropine and Biperiden.	Parkinsonism [8A00]	[14]
Levodopa	DMN3E57	Moderate	Altered absorption of Atropine due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[38]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Atropine and Orphenadrine.	Parkinsonism [8A00]	[14]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Atropine and Methylscopolamine.	Peptic ulcer [DA61]	[14]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Atropine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[14]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Atropine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[14]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Atropine and Quetiapine.	Schizophrenia [6A20]	[14]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Atropine and Mesoridazine.	Schizophrenia [6A20]	[14]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Atropine and Thioridazine.	Schizophrenia [6A20]	[14]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Atropine and Aripiprazole.	Schizophrenia [6A20]	[14]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Atropine and Iloperidone.	Schizophrenia [6A20]	[14]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Atropine and Paliperidone.	Schizophrenia [6A20]	[14]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Atropine and Perphenazine.	Schizophrenia [6A20]	[14]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Atropine and Molindone.	Schizophrenia [6A20]	[14]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Atropine and Thiothixene.	Schizophrenia [6A20]	[14]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Atropine and Trifluoperazine.	Schizophrenia [6A20]	[14]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Atropine and Risperidone.	Schizophrenia [6A20]	[14]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Atropine and Asenapine.	Schizophrenia [6A20]	[14]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Atropine and Pimozide.	Schizophrenia [6A20]	[14]
Fentanyl	DM8WAHT	Moderate	Additive antimotility effects by the combination of Atropine and Fentanyl.	Sensation disturbance [MB40]	[13]
Sufentanil	DMU7YEL	Moderate	Additive antimotility effects by the combination of Atropine and Sufentanil.	Sensation disturbance [MB40]	[13]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Atropine and Tizanidine.	Tonus and reflex abnormality [MB47]	[39]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Atropine due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[40]
Nitrofurantoin	DM7PQIK	Minor	Altered absorption of Atropine due to GI dynamics variation caused by Nitrofurantoin.	Urinary tract infection [GC08]	[41]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Atropine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[14]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Atropine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[14]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Atropine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[14]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Atropine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Atropine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[14]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Atropine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[14]
-----------


⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sulfuric acid	E00045	1118	Acidulant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Nitrogen	E00033	947	Aerosol propellant; Sparging agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent
Lanolin	E00375	75778	Emollient; Emulsifying agent; Ointment base
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Atropine 0.25mg/0.3ml solution	0.25mg/0.3ml	Solution	Intravenous
Atropine 0.5mg/0.7ml solution	0.5mg/0.7ml	Solution	Intravenous
Atropine 1mg/0.7ml solution	1mg/0.7ml	Solution	Intravenous
Atropine 2mg/0.7ml solution	2mg/0.7ml	Solution	Intravenous
Atropine 1mg/10ml solution	1mg/10ml	Solution	Intravenous
Atropine 1% ointment	1%	Ointment	Ophthalmic

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 320).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
6	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
7	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
8	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
9	Gene expression signature of parathion-transformed human breast epithelial cells. Int J Mol Med. 2007 May;19(5):741-50.
10	Assessment of false transmitters as treatments for nerve agent poisoning. Toxicol Lett. 2020 Mar 15;321:21-31. doi: 10.1016/j.toxlet.2019.12.010. Epub 2019 Dec 9.
11	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
14	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
15	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
16	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
17	Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
18	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
19	Multum Information Services, Inc. Expert Review Panel.
20	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
21	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
22	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
23	Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
24	Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
25	Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
26	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
27	Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
28	Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
29	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
30	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
31	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
32	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
33	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
34	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
35	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
36	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
37	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
38	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
39	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
40	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
41	Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]